Biosystems International and Microbiochips sign collaboration agreement to commer- cialize PlasmaScan™ antibody microarray products.
Biosystems International (BSI) a biotech- nology company focused on the development of novel monoclonal antibody-based diagnostics for cancer and metabolic diseases has established a licensing agreement with the Lohocla Research Corporation for the use of BSI’s patented monoclonal antibody proteo- mics platform for the discovery of novel alcoholism liver disease biomarkers in blood.
The innovative process created by BSI scientists, called monoclonal antibody proteomics combines several key technologies consisting of the chromatographic processing of human plasma, the high throughput generation of monoclonal antibodies (mAbs), and high throughput screening (HTS) to identify those antibodies which are suitable for further development for the production of microarrays and/or novel diagnostic products. The antibodies are furthermore used to identify the cognate antigen.
A Biosystems International felfedezett és létrehozott egy a plazma proteomban előforduló fehérjéket natív állapotban felismerő monoklonális ellenanyag könyvtárakat előállítani képes technológia platformot. E platform felhasználásával a human plasma proteom átfogó térképezésének első reális lehetősége nyílik meg.